219 results about "Hyperuricemia" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention relates to the technical field of biology, and particularly discloses a strain with a uric acid reducing characteristic and a growth-dependent uric acid characteristic, and the microbial preservation number of the strain is GDMCC No.65914. The uric acid reducing strain is screened from pickles by a transparent ring method, the 16S rRNA gene sequence of the uric acid reducing strain is studied, a resource library of the uric acid reducing strain is expanded, resources are provided for research and development of uric acid reducing drugs in the clinical field, non-target strains are effectively removed through a dual specific screening mechanism of uric acid dependent growth verification and liquid fermentation induced uric acid reduction, and the yield of the uric acid reducing strains is increased. The uric acid reduction and uric acid dependence function stability and metabolic specificity of the screened strain are ensured, the high uric acid reduction strain obtained through screening can be directly used for developing a novel microecological preparation or a uric acid reduction preparation, and compared with traditional chemical drugs, the high uric acid reduction strain has the advantages of being high in safety, good in biocompatibility and small in side effect; high-quality strain resources are provided for biological treatment of hyperuricemia and gout and development of uric acid detection reagents.

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

An Akk11 strain-containing probiotic agent capable of relieving hyperuricemia, and the use thereof. Strains in the probiotic agent include an Akkermansia muciniphila Akk11 strain and a Lactobacillus johnsonii LJ09 strain. It is found in the present application that the two strains possess a potential interaction and can cooperate with each other, thereby synergizing the effect of relieving hyperuricemia, which is specifically manifested in: being capable of remarkably regulating uric acid metabolism and improving renal clearance functions; being capable of effectively inhibiting the activity of a key enzyme for uric acid synthesis so as to reduce the production of uric acid, and being capable of remarkably relieving renal damage and renal dysfunctions associated with high levels of uric acid.

The invention relates to the technical field of medical informatics, in particular to an AI-based intelligent early warning system for hyperuricemia male reproductive metabolism abnormality. The system comprises a memory and a processor, and the processor executes a computer program stored in the memory to realize the following steps: acquiring uric acid data, waistline data, glycosylated hemoglobin data and reproductive index data of a target male; combining the uric acid fluctuation abnormality degree, the multi-dimensional blood glucose abnormality expression degree and the movement rule expression degree of each stage to obtain the reproduction metabolism abnormality degree; according to the relative relationship between the reproductive index data and the corresponding standard range, obtaining the abnormal performance degree of the reproductive index; integrating the reproductive metabolism abnormality degree and the reproductive index abnormality expression degree to obtain a multi-dimensional feature linkage reproductive metabolism expression comprehensive evaluation degree of the target male; and according to the comprehensive evaluation degree of the multi-dimensional feature linkage reproductive metabolism performance, whether early warning is carried out is judged. According to the invention, the accuracy and credibility of intelligent early warning of the risk of abnormal male reproductive metabolism of hyperuricemia are improved.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention provides a hyperuricemia high-risk screening system and method based on big data, and relates to the technical field of big data deep learning, and the method comprises the steps: collecting feature data related to hyperuricemia from a plurality of data sources, carrying out the data preprocessing, calculating a related feature index based on the preprocessed data, and building a convolutional neural network model, thereby achieving the high-risk screening of hyperuricemia. The method comprises the following steps: inputting a feature index, outputting a hyperuricemia risk level, then obtaining feature data of a person to be screened, inputting a trained model, generating a risk level correction coefficient in combination with personal information, and finally determining a final hyperuricemia risk level index by setting an upgrading and degrading mechanism and comparing the correction coefficient with a preset threshold value. According to the method, feature data related to hyperuricemia are collected through multiple data sources, and accurate assessment of the hyperuricemia risk is realized in combination with the convolutional neural network model.

The invention discloses application of benzofuran components in eupatorium chinense to reduction of uric acid, compounds 1-3 are obtained by being separated from an eupatorium chinense extract, and the compound 1 is a new compound. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, HW-40F gel column chromatography, high performance liquid chromatography and other methods to obtain the benzofuran compound. According to the present invention, the inhibition activity of the gout disease related target xanthine oxidase of the separated compound 1-3 is tested, the experimental result shows that the compound 1-3 has good inhibition activity on the xanthine oxidase, and the molecular docking experiment shows that the compound 1-3 has good binding energy with the target protein. Therefore, the compounds 1-3 can be used for preparing a natural lead compound for delaying or treating diseases caused by xanthine oxidase and providing a natural lead compound in the field of treatment of hyperuricemia and gout.

To provide development of health food supplements and antioxidants for controlling hyperuricemia and oxidative stress.SOLUTION: Embodiments of the disclosure include methods and compositions that comprise one or more herb extracts and optionally folic acid and / or one or more of its derivatives. In specific embodiments, the disclosure concerns treatment or prevention of hyperuricemic conditions with combinatorial compositions, such as those including one or more Chinese herbal medicine extracts and optionally folic acid and / or one or more of its derivatives.SELECTED DRAWING: None

This invention discloses the XO-inhibiting peptide GDEY and its applications, belonging to the field of bioactive peptide technology. The amino acid sequence of the XO-inhibiting peptide GDEY is shown in SEQ ID NO.2. The invention also discloses the application of the XO-inhibiting peptide GDEY in the preparation of xanthine oxidase inhibitors and in the preparation of drugs with the effect of inhibiting uric acid levels. This invention used molecular docking and BLAST+ software to virtually screen 15 potential XO-inhibiting peptides from the complete protein sequence of Litopenaeus vannamei. High-performance liquid chromatography (HPLC) was used to determine the XO-inhibiting activity, and the results showed that 7 small molecule peptides exhibited significant XO-inhibiting activity, possessing potential value in preventing hyperuricemia.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.

The application discloses a tetrapeptide IR4 with uric acid reducing activity, and a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared by a solid-phase synthesis method and an enzymatic hydrolysis method. The tetrapeptide IR4 is identified from a porphyra haitanensis protease hydrolysate, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 33.6% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with an anserine (which can reduce the uric acid content of zebrafish by 25.7%), the tetrapeptide IR4 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the tetrapeptide IR4 and the allopurinol has no significant difference. The tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.

The invention belongs to the technical field of biology, and particularly relates to regulation and control of cinnamyl aldehyde on hyperuricemia related gene promoter region G quadruplex. According to the application disclosed by the invention, firstly, the capacity of cinnamyl aldehyde for regulating and controlling a G quadruplex in a hyperuricemia related gene promoter region is explored by utilizing circular dichroism, and the influence of cinnamyl aldehyde on regulation and control of a nucleic acid structure is further evaluated by utilizing a fluorospectro photometer, so that support is provided for a molecular mechanism of cinnamyl aldehyde for relieving hyperuricemia on a gene level. In conclusion, the invention discloses a brand new mechanism that cinnamyl aldehyde regulates and controls uric acid metabolism related genes through a targeted G quadruplex structure, a precise action target and a potential drug development direction are provided for treatment of hyperuricemia, and meanwhile, an established small molecule and G quadruplex interaction verification method provides technical reference for similar research.

The present invention belongs to the field of biomedicine technology, and in particular relates to a sea cucumber sand spit active peptide with xanthine oxidase inhibitory activity, and its preparation method and application. The sea cucumber sand spit active peptide provided by the present invention contains at least one of FPF and WFP, has high xanthine oxidase inhibitory activity, can achieve uric acid lowering function by inhibiting xanthine oxidase activity, and can be used to prepare uric acid lowering drugs. The sea cucumber sand spit active peptide is prepared from the sand spit, a by-product of sea cucumber processing, as a raw material through bio-enzymatic hydrolysis technology under a specific process, which not only solves the problem of low utilization rate of sea cucumber processing by-products, but also reduces resource waste. The present invention provides a green and sustainable auxiliary intervention program for patients with hyperuricemia and gout, and at the same time provides an innovative way to high-value utilization of marine processing waste.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine composition for treating damp turbidity and blood stasis type hyperuricemia or gout and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 12-18 parts of radix paeoniae alba, 12-18 parts of yam rhizome, 45-55 parts of rhizoma smilacis glabrae, 25-35 parts of plantain herb, 8-12 parts of radix polygonati officinalis, 8-12 parts of radix cyathulae, 8-12 parts of fructus psoraleae, 7-11 parts of ground beeltle and 3-7 parts of liquorice. The traditional Chinese medicine composition is formulated according to the traditional Chinese medicine pathogenesis characteristics of hyperuricemia and gout, the whole formula takes improvement of intestinal mucosa barrier as the core, the effects of reducing the blood uric acid level, relieving symptoms and conditioning the body are achieved through diuresis promoting, turbidity removing, collateral dredging and blood stasis removing, and the traditional Chinese medicine composition is suitable for gout and hyperuricemia caused by intestinal damp turbidity and blood stasis blocking.

The invention relates to the technical field of preparation of deep-sea longevity fish precise active peptides, in particular to a deep-sea longevity fish precise active peptide with uric acid reducing and anti-inflammatory effects as well as a preparation method and application of the deep-sea longevity fish precise active peptide. The preparation method comprises the following steps: carrying out medium-temperature pretreatment, carrying out step-by-step enzymolysis with alkaline protease and acid protease, centrifuging, filtering, carrying out ultrafiltration interception and the like, and screening out 10 non-reported non-toxic active peptide fragments. The active peptide has a multi-target synergistic effect, inhibits the activity of xanthine oxidase, regulates and controls the expression of uric acid resorption protein, regulates and controls the expression of uric acid transporter protein, realizes bidirectional regulation of uric acid metabolism, efficiently removes hydroxyl radicals, activates superoxide dismutase and reduces the content of inflammation-related factors. The technology is simple and easy to control, low in equipment requirement and suitable for large-scale production, the active ingredients are natural, safety is high, the active ingredients can serve as functional factors to be applied to functional food, health care products and the like, and safe and diversified intervention schemes are provided for hyperuricemia and related inflammation problems.

The present application relates to the field of food processing technology, and provides a method and a device for purine reduction, and an equipment and an electronic equipment and a storage medium. The method for purine reduction includes the following steps: first cooling step: performing first cooling treatment on a food material to be treated at a first preset cooling rate to reduce a temperature of the food material to be treated to a temperature below a freezing point. By performing first cooling treatment on a food material to be treated at a first preset cooling rate to reduce a temperature of the food material to be treated to a temperature below a freezing point, the activity of ATP-degrading enzyme in the food material to be treated can be rapidly inhibited, which can quickly and effectively inhibit the generation of hypoxanthine, thereby reducing the generation of hypoxanthine, reducing the risk of hyperuricemia and gout, and having little effect on the taste and quality of the food material.

The application discloses a small molecule peptide AGGINLAR, and an amino acid sequence of the small molecule peptide is shown as SEQ ID NO. 3. The small molecule peptide is applied to preparation of a xanthine oxidase inhibitor and preparation of a drug for treating or preventing hyperuricemia. Through experimental research, six small molecule peptides with xanthine oxidase inhibiting activity are screened from enzymatic hydrolysate of Penaeus vannamei, and the small molecule peptides have the potential of serving as xanthine oxidase inhibitors, wherein AGGINLAR shows higher xanthine oxidase inhibiting activity, and has greater potential value in preventing hyperuricemia.

The invention belongs to the technical field of biological fermentation, and particularly relates to a preparation method and application of a fermented rhizoma smilacis glabrae extract. The invention relates to a fermented rhizoma smilacis glabrae extract, which is characterized in that a lactobacillus rhamnosus LR.M8 strain is utilized, the inhibition effect of the rhizoma smilacis glabrae extract on xanthine oxidase is improved through fermentation, and the treatment effect of the rhizoma smilacis glabrae extract on hyperuricemia is improved. The solution for improving the effect of the extract through biological fermentation is provided for solving the problems that the content of effective components in common medicinal and edible extracts is low, and the human body utilization rate is not high. The lactobacillus rhamnosus LR.M8 can effectively improve the adjusting effect of the rhizoma smilacis glabrae medicine and food homologous plant extract on uric acid balance, can reduce damage of inflammation to cells, and promotes in-vivo purine metabolism to recover balance. The fermentation method provided by the invention is simple and remarkable in effect, and has a wide application prospect.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid-reducing health-care products. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.